The compact shielded MRI platform from Aspect Imaging utilizes a high-performance 1T magnet with powerful gradients and no external magnetic fringe field. High spatial resolution of up to 100 µm together with superb soft tissue contrast result in exquisite 3D anatomical/morphological imaging. The permanent magnet platform provides a maintenance-free, easy-to-use MRI solution with a small footprint and with easy, rapid installation. It is optimized to perform fast, high-throughput imaging across a variety of applications and preclinical studies without the need of any special expertise.
"The high resolution capability and ease of use of the Aspect Imaging M2™ platform perfectly complements Mediso's cutting edge nanoScan technology," says Uri Rapoport, Aspect Imaging's Founder and CEO. "The combination of high-resolution SPECT and high-performance compact MRI will provide significant benefit to academic and pharmaceutical researchers who are looking for additional flexibility and performance from their translational imaging tools". Aspect Imaging has placed significant resources and MR expertise to support the M2 compact high-performance MRI system which is manufactured for and sold to Mediso as a key component of its nanoScan® platform. Aspect has a long term commitment to maintain a full development and support team at its headquarters in Shoham, Israel that actively works on the M2 platform.
Ad Statistics
Times Displayed: 113248
Times Visited: 6741 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
The nanoScan® SPECT/MRI is perfectly suited as a powerful multi-modality solution for quantified imaging in the following preclinical application areas: oncology and tumor biology, regenerative medicine, receptor studies in neuroscience, inflammation and immunology, infectious diseases, animal model development, phenotyping and development of radiotracers and contrast agents.
The first nanoScan® SPECT/MRI system is being evaluated in the Nanobiotechnology and In vivo Imaging Centre jointly operated by Semmelweis University and CROmed Ltd. The nanoScan® SPECT/MRI is the optimal imaging choice for whose research requires the finest radiotracer imaging technology along with the robust support and co-registration with high-resolution MRI images. "The combined nanoScan® SPECT/MRI provides a fascinating novel method to characterise circulating molecules with long biological half-life without limits in soft tissue contrast and volumetric resolution", says Dr Domokos Mathe, CEO of CROmed.
The nanoScan® SPECT/MRI in-line multimodality pre-clinical imager is developed, manufactured and distributed by Mediso worldwide and can be seen at the World Molecular Imaging Congress (WMIC) in Dublin, Ireland at Mediso's booth #217.
